Intraventricular haemorrhage · very preterm infants at risk of intraventricular hemorrhage
Antithrombin showed no clear difference in intraventricular hemorrhage (any severity, grade 1 to 4) compared with placebo (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · very preterm infants at risk of intraventricular hemorrhage
Antithrombin showed no clear difference in severe Intraventricular hemorrhage (grade 3 to 4) compared with placebo (low certainty).
1 finding from 1 review
Neonatal mortality · very preterm infants at risk of intraventricular hemorrhage
It is very uncertain whether antithrombin changes neonatal mortality (all‐cause, < 28 days of age) compared with placebo (very low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
It is very uncertain whether antithrombin changes major bleeding compared with no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic DVT · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
It is very uncertain whether antithrombin changes any VTE compared with no thromboprophylaxis (very low certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).
1 finding from 1 review
First‐time symptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Major bleeding · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).
1 finding from 1 review
Quality of life ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asymptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Clinically relevant non‐major bleeding ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found